久久一区二区三区四区_欧美高清dvd_日韩欧美在线看_国产精品欧美一区二区_av天天看_欧美精品免费观看二区

MicuRx 盟科醫(yī)藥  
MicuRx 致力于發(fā)現(xiàn)和開發(fā)治療由耐藥菌引起感染的新型抗生素。該公司將其美國研發(fā)團隊的豐富經(jīng)驗與中國高品質(zhì)、高經(jīng)濟效益的藥物研發(fā)優(yōu)勢相結(jié)合，逐漸建立起一個治療各類耐藥革蘭氏陽性和陰性菌新藥的平臺。該公司在美國加州硅谷和中國張江設(shè)有研發(fā)實驗室。MicuRx 在首輪風險融資中從 Morningside Group 和 Devon Park Bioventures  募集了1200萬美元。

 
盟科醫(yī)藥技術(shù)（上海）有限公司成立于2007年7月,致力于開發(fā)擁有自主知識產(chǎn)權(quán)的新一代抗菌藥物，以解決日益嚴重的、由于耐藥菌引起的感染，并在未來實現(xiàn)其工業(yè)生產(chǎn)和商業(yè)化。
經(jīng)過三年多的高效運轉(zhuǎn)，公司自主研發(fā)的第一個候選1.1類新藥MRX-I，其前期研究得到了國家“十一五重大新藥創(chuàng)制”的一定支持，現(xiàn)已完成了前期藥學(xué)，毒理和生產(chǎn)工藝的研究，于2009年在中國申報臨床試驗（IND），并已取得中國食品藥品監(jiān)督管理局進行臨床試驗的批文，已經(jīng)進入一期人體臨床試驗。該1.1類新藥有望于2015年前后在中、美同時上市，預(yù)期全球市場可達十億美元。
   


MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient infrastructure and scientific resources available in China. This hybrid business model enables MicuRx to implement an accelerated global development strategy with a goal of completing Phase II trials for its drug candidates in both the United States and China.

Infections due to multi-drug resistant bacteria have become a major threat to public health. In particular, methicillin-resistant Staphylococcus aureus (MRSA) has quickly spread from the hospital setting into the community and vancomycin-resistant enterococci (VRE) now represents at least 30% of all hospital enterococci infections. Importantly, bacteria continue to evolve and new strains of bacteria are resistant to even the newest antibiotics.

Using its proprietary drug discovery platform, MicuRx has generated a broad pipeline of antimicrobial agents to treat Gram-positive, Gram-negative and fungal infections. MicuRx's lead drug candidate is MRX-I, a next-generation oxazolidinone antibiotic with a superior therapeutic window projected to offer significant clinical differences over existing drugs. MicuRx filed its first Investigational New Drug (IND) application in China and received "Special Review" status from the State Food and Drug Administration.

In addition to its internal pipeline, MicuRx and Pfizer have entered a collaboration agreement to discover and develop new therapeutic agents to treat drug-resistant tuberculosis. All collaboration research will be conducted at the ZhangJiang High-Tech Park in Shanghai, China.